XIGDUO XR 5 MG1000 MG Izrael - angielski - Ministry of Health

xigduo xr 5 mg1000 mg

astrazeneca (israel) ltd - dapagliflozin propanediol; metformin hydrochloride - tablets extended release - metformin hydrochloride 1005.04 mg; dapagliflozin propanediol 6.150 mg - metformin and dapagliflozin - xigduo xr (dapagliflozin and metformin hcl extended-release) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate.

XIGDUO XR 5 MG1000 MG Izrael - angielski - Ministry of Health

xigduo xr 5 mg1000 mg

astrazeneca (israel) ltd - dapagliflozin propanediol; metformin hydrochloride - tablets extended release - metformin hydrochloride 1005.04 mg; dapagliflozin propanediol 6.150 mg - metformin and dapagliflozin - xigduo xr (dapagliflozin and metformin hcl extended-release) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate.שינוי משטר מינון 2/4/2019patients with renal impairment

XIGDUO XR 5 MG500 MG Izrael - angielski - Ministry of Health

xigduo xr 5 mg500 mg

astrazeneca (israel) ltd - dapagliflozin propanediol; metformin hydrochloride - tablets extended release - metformin hydrochloride 502.61 mg; dapagliflozin propanediol 6.150 mg - metformin and dapagliflozin - xigduo xr (dapagliflozin and metformin hcl extended-release) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate.

XIGDUO XR 5 MG500 MG Izrael - angielski - Ministry of Health

xigduo xr 5 mg500 mg

astrazeneca (israel) ltd - dapagliflozin propanediol; metformin hydrochloride - tablets extended release - metformin hydrochloride 502.61 mg; dapagliflozin propanediol 6.150 mg - metformin and dapagliflozin - xigduo xr (dapagliflozin and metformin hcl extended-release) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate.

XIGDUO XR TABLET 101000MG Malezja - angielski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

xigduo xr tablet 101000mg

astrazeneca sdn. bhd. - metformin hydrochloride; dapagliflozin propanediol -

XIGDUO XR TABLET 51000MG Malezja - angielski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

xigduo xr tablet 51000mg

astrazeneca sdn. bhd. - metformin hydrochloride; dapagliflozin propanediol -

XIGDUO XR TABLET 10500MG Malezja - angielski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

xigduo xr tablet 10500mg

astrazeneca sdn. bhd. - metformin hydrochloride; dapagliflozin propanediol -

XIGDUO XR 10/500 dapagliflozin 10 mg (as propanediol monohydrate) / metformin hydrochloride 500 mg modified release tablets blister pack Australia - angielski - Department of Health (Therapeutic Goods Administration)

xigduo xr 10/500 dapagliflozin 10 mg (as propanediol monohydrate) / metformin hydrochloride 500 mg modified release tablets blister pack

astrazeneca pty ltd - metformin hydrochloride, quantity: 500 mg; dapagliflozin propanediol monohydrate, quantity: 12.3 mg (equivalent: dapagliflozin, qty 10 mg) - tablet, modified release - excipient ingredients: microcrystalline cellulose; lactose; silicon dioxide; hypromellose; crospovidone; carmellose sodium; magnesium stearate; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - glycaemic control: xigduo xr is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control when treatment with both dapagliflozin and metformin is appropriate,prevention of hospitalisation for heart failure: xigduo xr is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease or risk factors for cardiovascular disease to reduce the risk of hospitalization for heart failure,(see section 5.1 pharmacodynamic properties ? clinical trials and 4.4 special warnings and precautions for use for available data on the combination therapy).

Xigduo XR 5 mg/1000 mg, extended release tablets Kenia - angielski - Pharmacy and Poisons Board

xigduo xr 5 mg/1000 mg, extended release tablets

dapagliflozin and metformin hydrochloride - tablet - each xigduo xr 5mg / 1000mg tablet contains the… - metformin and dapagliflozin

XIGDUO XR 5/1000 dapagliflozin 5 mg (as propanediol monohydrate) / metformin hydrochloride 1000 mg modified release tablets blister pack Australia - angielski - Department of Health (Therapeutic Goods Administration)

xigduo xr 5/1000 dapagliflozin 5 mg (as propanediol monohydrate) / metformin hydrochloride 1000 mg modified release tablets blister pack

astrazeneca pty ltd - dapagliflozin propanediol monohydrate, quantity: 6.15 mg (equivalent: dapagliflozin, qty 5 mg); metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: carmellose sodium; lactose; hypromellose; silicon dioxide; crospovidone; magnesium stearate; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - glycaemic control: xigduo xr is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control when treatment with both dapagliflozin and metformin is appropriate,prevention of hospitalisation for heart failure: xigduo xr is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease or risk factors for cardiovascular disease to reduce the risk of hospitalization for heart failure,(see section 5.1 pharmacodynamic properties ? clinical trials and 4.4 special warnings and precautions for use for available data on the combination therapy).